<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: More than half of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> will develop <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> either evident at the time of initial diagnosis or during their course of disease </plain></SENT>
<SENT sid="1" pm="."><plain>Besides multidisciplinary management further treatment intensification is warranted to improve the still limited prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS/DESIGN: In these two multi-centre, randomized phase II trials, conducted in Germany, 380 patients with R0-resectable colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> (PERIMAX) and with unresectable, <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (CHARTA) will be recruited </plain></SENT>
<SENT sid="3" pm="."><plain>Patients previously untreated for <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> with either synchronous or metachronous <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> are randomly assigned in a 1:1 ratio to resection of colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> followed by postoperative FOLFOX for 6 months or perioperative FOLFOXIRI and bevacizumab for 3 months pre- and postoperative and resection (PERIMAX), or to induction chemotherapy with FOLFOX and bevacizumab +/- irinotecan for a maximum of 6 months followed by maintenance treatment with fluoropyrimidine and bevacizumab </plain></SENT>
<SENT sid="4" pm="."><plain>The primary objective of these trials is to evaluate the feasibility and efficacy of FOLFOXIRI and bevacizumab in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Primary endpoint is failure free survival rate at 18 months in the PERIMAX trial and progression free survival rate at 9 months in CHARTA </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary objectives include efficacy, safety and tolerability </plain></SENT>
<SENT sid="7" pm="."><plain>DISCUSSION: The CHARTA and PERIMAX trials are designed to evaluate the benefits and limitations of a highly active four-drug regimen in distinct treatment situations of metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Eligible patients are classified into resectable <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> to be randomized to perioperative treatment with FOLFOXIRI and bevacizumab or postoperative FOLFOX in the PERIMAX, or unresectable metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> to be randomized between FOLFOX and bevacizumab with or without irinotecan, stratified for clinical groups according to disease and patients' characteristics in the CHARTA trial </plain></SENT>
<SENT sid="9" pm="."><plain>TRIAL REGISTRATION: Clinical trial identifier CHARTA: NCT01321957, PERIMAX: NCT01540435 </plain></SENT>
</text></document>